Search

Your search keyword '"Saar, I."' showing total 138 results
Start Over Author "Saar, I." Publication Year Range Last 3 years
138 results on '"Saar, I."'

1. Long-term safety of lentiviral or gammaretroviral gene-modified T cell therapies

Author

Jadlowsky, Julie K., Hexner, Elizabeth O., Marshall, Amy, Grupp, Stephan A., Frey, Noelle V., Riley, James L., Veloso, Elizabeth, McConville, Holly, Rogal, Walter, Czuczman, Cory, Hwang, Wei-Ting, Li, Yimei, Leskowitz, Rachel M., Farrelly, Olivia, Karar, Jayashree, Christensen, Shannon, Barber-Rotenberg, Julie, Gaymon, Avery, Aronson, Naomi, Bernstein, Wendy, Melenhorst, Jan Joseph, Roche, Aoife M., Everett, John K., Zolnoski, Sonja A., McFarland, Alexander G., Reddy, Shantan, Petrichenko, Angelina, Cook, Emma J., Lee, Carole, Gonzalez, Vanessa E., Alexander, Kathleen, Kulikovskaya, Irina, Ramírez-Fernández, Ángel, Minehart, Janna C., Ruella, Marco, Gill, Saar I., Schuster, Stephen J., Cohen, Adam D., Garfall, Alfred L., Shah, Payal D., Porter, David L., Maude, Shannon L., Levine, Bruce L., Siegel, Donald L., Chew, Anne, McKenna, Stephen, Lledo, Lester, Davis, Megan M., Plesa, Gabriela, Herbst, Friederike, Stadtmauer, Edward A., Tebas, Pablo, DiNofia, Amanda, Haas, Andrew, Haas, Naomi B., Myers, Regina, O’Rourke, Donald M., Svoboda, Jakub, Tanyi, Janos L., Aplenc, Richard, Jacobson, Jeffrey M., Ko, Andrew H., Cohen, Roger B., June, Carl H., Bushman, Frederic D., and Fraietta, Joseph A.

Published
2025
Full Text
View/download PDF

2. Cytokine-mediated CAR T therapy resistance in AML

Author

Bhagwat, Anand S., Torres, Leonel, Shestova, Olga, Shestov, Maksim, Mellors, Patrick W., Fisher, Han R., Farooki, Saamia N., Frost, Benjamin F., Loken, Michael R., Gaymon, Avery L., Frazee, Diane, Rogal, Walter, Frey, Noelle, Hexner, Elizabeth O., Luger, Selina M., Loren, Alison W., Martin, Mary Ellen, McCurdy, Shannon R., Perl, Alexander E., Stadtmauer, Edward A., Brogdon, Jennifer L., Fraietta, Joseph A., Hwang, Wei-Ting, Siegel, Don L., Plesa, Gabriela, Aplenc, Richard, Porter, David L., June, Carl H., and Gill, Saar I.

Published
2024
Full Text
View/download PDF

6. Hypomethylating agents are associated with high rates of hematologic toxicity in patients with secondary myeloid neoplasms developing after acquired aplastic anemia

Author

Matthew P. Connor, Neeharika Prathapa, Noelle V. Frey, Saar I. Gill, Elizabeth O. Hexner, Ximena Jordan Bruno, Catherine E. Lai, Alison W. Loren, Selina M. Luger, Andrew H. Matthews, Shannon R. McCurdy, Alexander E Perl, David L. Porter, Arlene Zeringue, Joseph H. Oved, Timothy S. Olson, Keith W. Pratz, and Daria V. Babushok

Subjects
Diseases of the blood and blood-forming organs, RC633-647.5
Abstract

Not available.

Published
2024
Full Text
View/download PDF

9. Real-world effectiveness of CPX-351 vs venetoclax and azacitidine in acute myeloid leukemia

Author

Matthews, Andrew H., Perl, Alexander E., Luger, Selina M., Loren, Alison W., Gill, Saar I., Porter, David L., Babushok, Daria V., Maillard, Ivan P., Carroll, Martin P., Frey, Noelle V., Hexner, Elizabeth O., Martin, Mary Ellen, McCurdy, Shannon R., Stadtmauer, Edward A., Paralkar, Vikram R., Bruno, Ximena Jordan, Hwang, Wei-Ting, Margolis, David, and Pratz, Keith W.

Published
2022
Full Text
View/download PDF

10. Author Correction: Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy

Author

Smith, Melody, Dai, Anqi, Ghilardi, Guido, Amelsberg, Kimberly V., Devlin, Sean M., Pajarillo, Raymone, Slingerland, John B., Beghi, Silvia, Herrera, Pamela S., Giardina, Paul, Clurman, Annelie, Dwomoh, Emmanuel, Armijo, Gabriel, Gomes, Antonio L. C., Littmann, Eric R., Schluter, Jonas, Fontana, Emily, Taur, Ying, Park, Jae H., Palomba, Maria Lia, Halton, Elizabeth, Ruiz, Josel, Jain, Tania, Pennisi, Martina, Afuye, Aishat Olaide, Perales, Miguel-Angel, Freyer, Craig W., Garfall, Alfred, Gier, Shannon, Nasta, Sunita, Landsburg, Daniel, Gerson, James, Svoboda, Jakub, Cross, Justin, Chong, Elise A., Giralt, Sergio, Gill, Saar I., Riviere, Isabelle, Porter, David L., Schuster, Stephen J., Sadelain, Michel, Frey, Noelle, Brentjens, Renier J., June, Carl H., Pamer, Eric G., Peled, Jonathan U., Facciabene, Andrea, van den Brink, Marcel R. M., and Ruella, Marco

Published
2023
Full Text
View/download PDF

11. Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy

Author

Smith, Melody, Dai, Anqi, Ghilardi, Guido, Amelsberg, Kimberly V., Devlin, Sean M., Pajarillo, Raymone, Slingerland, John B., Beghi, Silvia, Herrera, Pamela S., Giardina, Paul, Clurman, Annelie, Dwomoh, Emmanuel, Armijo, Gabriel, Gomes, Antonio L. C., Littmann, Eric R., Schluter, Jonas, Fontana, Emily, Taur, Ying, Park, Jae H., Palomba, Maria Lia, Halton, Elizabeth, Ruiz, Josel, Jain, Tania, Pennisi, Martina, Afuye, Aishat Olaide, Perales, Miguel-Angel, Freyer, Craig W., Garfall, Alfred, Gier, Shannon, Nasta, Sunita, Landsburg, Daniel, Gerson, James, Svoboda, Jakub, Cross, Justin, Chong, Elise A., Giralt, Sergio, Gill, Saar I., Riviere, Isabelle, Porter, David L., Schuster, Stephen J., Sadelain, Michel, Frey, Noelle, Brentjens, Renier J., June, Carl H., Pamer, Eric G., Peled, Jonathan U., Facciabene, Andrea, van den Brink, Marcel R. M., and Ruella, Marco

Published
2022
Full Text
View/download PDF

13. WS06.06 Safety and efficacy of a nebulized phage cocktail in cystic fibrosis patients with chronic Pseudomonas aeruginosa pulmonary infection: a phase 1b/2a randomized, double-blind, placebo-controlled study

Author

Kerem, E., primary, Rappo, U., additional, Cohen, A., additional, Maimon, I., additional, Kario, E., additional, Gold, J., additional, Nevenzal, H.-T., additional, Levy-Saar, I., additional, Cohen, T., additional, Weiner, I., additional, Livnat, H. Sberro, additional, Slutskin, I. Vainberg, additional, Jablonska, J., additional, Mordoch, R., additional, Axelrod, T., additional, Bahar, O., additional, Buchshtab, N., additional, Lev, V., additional, Tzur, Y., additional, Zarchin, Y., additional, Golembo, M., additional, Vilchez, R., additional, and Bassan, M., additional

Published
2024
Full Text
View/download PDF

14. Decade-long leukaemia remissions with persistence of CD4+ CAR T cells

Author

Melenhorst, J. Joseph, Chen, Gregory M., Wang, Meng, Porter, David L., Chen, Changya, Collins, McKensie A., Gao, Peng, Bandyopadhyay, Shovik, Sun, Hongxing, Zhao, Ziran, Lundh, Stefan, Pruteanu-Malinici, Iulian, Nobles, Christopher L., Maji, Sayantan, Frey, Noelle V., Gill, Saar I., Loren, Alison W., Tian, Lifeng, Kulikovskaya, Irina, Gupta, Minnal, Ambrose, David E., Davis, Megan M., Fraietta, Joseph A., Brogdon, Jennifer L., Young, Regina M., Chew, Anne, Levine, Bruce L., Siegel, Donald L., Alanio, Cécile, Wherry, E. John, Bushman, Frederic D., Lacey, Simon F., Tan, Kai, and June, Carl H.

Published
2022
Full Text
View/download PDF

15. Rapid manufacturing of non-activated potent CAR T cells

Author

Ghassemi, Saba, Durgin, Joseph S., Nunez-Cruz, Selene, Patel, Jai, Leferovich, John, Pinzone, Marilia, Shen, Feng, Cummins, Katherine D., Plesa, Gabriela, Cantu, Vito Adrian, Reddy, Shantan, Bushman, Frederic D., Gill, Saar I., O’Doherty, Una, O’Connor, Roddy S., and Milone, Michael C.

Published
2022
Full Text
View/download PDF

16. Preconditioning Frailty Phenotype Influences Survival and Relapse for Older Allogeneic Transplantation Recipients

Author

Sung, Anthony D., Koll, Thuy, Gier, Shannon H., Racioppi, Alessandro, White, Griffin, Lew, Meagan, Free, Marcia, Agarwal, Priyal, Bohannon, Lauren M., Johnson, Ernaya J., Selvan, Bharathi, Babushok, Daria V., Frey, Noelle V., Gill, Saar I., Hexner, Elizabeth O., Martin, MaryEllen, Perl, Alexander E., Pratz, Keith W., Luger, Selina M., Chao, Nelson J., Fisher, Alfred L., Stadtmauer, Edward A., Porter, David L., Loren, Alison W., Bhatt, Vijaya R., Gimotty, Phyllis A., and McCurdy, Shannon R.

Published
2024
Full Text
View/download PDF

17. Author Correction: Decade-long leukaemia remissions with persistence of CD4+ CAR T cells

Author

Melenhorst, J. Joseph, Chen, Gregory M., Wang, Meng, Porter, David L., Chen, Changya, Collins, McKensie A., Gao, Peng, Bandyopadhyay, Shovik, Sun, Hongxing, Zhao, Ziran, Lundh, Stefan, Pruteanu-Malinici, Iulian, Nobles, Christopher L., Maji, Sayantan, Frey, Noelle V., Gill, Saar I., Loren, Alison W., Tian, Lifeng, Kulikovskaya, Irina, Gupta, Minnal, Ambrose, David E., Davis, Megan M., Fraietta, Joseph A., Brogdon, Jennifer L., Young, Regina M., Chew, Anne, Levine, Bruce L., Siegel, Donald L., Alanio, Cécile, Wherry, E. John, Bushman, Frederic D., Lacey, Simon F., Tan, Kai, and June, Carl H.

Published
2022
Full Text
View/download PDF

18. Interim Results of a Phase I/II Trial of Intermediate-Dose Post-Transplantation Cyclophosphamide after Reduced Intensity Conditioned HLA-Mismatched Bone Marrow Transplantation for Older or Unfit Patients

Author

McCurdy, Shannon R., primary, Hyder, Mustafa A., additional, Sabina, Ruby, additional, DeVries, Ashley, additional, Chalupa, Kirstin, additional, Berryman, Natasha, additional, Bernhardt, Jessica, additional, Cusmano, Alison Christina, additional, Chai, Amy, additional, Schwartz, Rebecca, additional, Dimitrova, Dimana, additional, Rechache, Kamil, additional, McKeown, Christi, additional, Stokes, Anita, additional, Sponaugle, Jennifer, additional, Frey, Noelle V., additional, Gill, Saar I., additional, Hexner, Elizabeth O, additional, Martin, Mary Ellen, additional, Hossain, Nasheed, additional, Porter, David L., additional, Loren, Alison W., additional, Kanakry, Jennifer A., additional, and Kanakry, Christopher G., additional

Published
2024
Full Text
View/download PDF

19. Post-Transplant Frailty Phenotype Predicts Survival

Author

Hadjis, Ashley D., primary, White, Griffin W., additional, Gill, Saar I., additional, Hossain, Nasheed, additional, Frey, Noelle V., additional, Hexner, Elizabeth O, additional, Bruno, Ximena Jordan, additional, Lai, Catherine E, additional, Matthews, Andrew H., additional, Martin, Mary Ellen, additional, Babushok, Daria V., additional, Perl, Alexander E., additional, Pratz, Keith W., additional, Luger, Selina M., additional, Porter, David L., additional, Loren, Alison W., additional, and McCurdy, Shannon R., additional

Published
2024
Full Text
View/download PDF

20. One versus two sets of busulfan therapeutic drug monitoring in myeloablative allogeneic hematopoietic cell transplant.

Author

Chippendale, Lindsey, Freyer, Craig W, Carulli, Alison, Babushok, Daria V, Frey, Noelle V, Gill, Saar I, Hexner, Elizabeth O, Luger, Selina M, Martin, Mary Ellen, Porter, David L, Stadtmauer, Edward A, and Loren, Alison W

Subjects
HEMATOPOIETIC stem cell transplantation, GRAFT versus host disease, STOMATITIS, BUSULFAN, TREATMENT effectiveness, DRUG monitoring, DISEASE relapse, HEPATIC veno-occlusive disease, PROGRESSION-free survival, OVERALL survival
Abstract

Introduction: Busulfan is a common component of allogeneic hematopoietic cell transplant (alloHCT) conditioning, however interpatient pharmacokinetic variability can result in enhanced toxicity or increased relapse risk. Therapeutic drug monitoring (TDM) can minimize variability, yet the optimal frequency of TDM is unknown. We compared outcomes for patients with one versus two sets of busulfan TDM during myeloablative conditioning (MAC) prior to alloHCT. Methods: We analyzed the impact of busulfan TDM frequency and dose adjustments, with the primary outcome being relapse-free survival (RFS). Other outcomes included the incidence of acute and chronic graft versus host disease (GVHD), oral mucositis, pulmonary toxicity, sinusoidal obstruction syndrome (SOS), the cumulative incidence of relapse (CIR), and overall survival (OS). Results: Twenty-two patients underwent one set of sampling while 53 patients underwent two sets. Similar baseline characteristics were observed between the groups. There were no significant differences observed in RFS by day +180 (77.3% vs. 79.2%, p = 1.0), CIR by day +180 (18.2% vs. 17.8%, p = 0.74), or OS (p = 0.73). The incidences of acute GVHD, chronic GVHD, SOS, and severe mucositis were also similar. In each group, 63% received busulfan dose adjustments after one set, with 52.8% receiving further dose adjustments following the second set. Conclusion: We observed no significant difference in alloHCT outcomes between patients who underwent one versus two sets of busulfan TDM sampling, suggesting that a single-time TDM and dose adjustment may be adequate to maximize outcomes after MAC alloHCT. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

22. Epitope base editing CD45 in hematopoietic cells enables universal blood cancer immune therapy

Author

Wellhausen, Nils, primary, O’Connell, Ryan P., additional, Lesch, Stefanie, additional, Engel, Nils W., additional, Rennels, Austin K., additional, Gonzales, Donna, additional, Herbst, Friederike, additional, Young, Regina M., additional, Garcia, K. Christopher, additional, Weiner, David, additional, June, Carl H., additional, and Gill, Saar I., additional

Published
2023
Full Text
View/download PDF

23. Clofarabine and Busulfan Myeloablative Conditioning in Allogeneic Hematopoietic Cell Transplantation for Patients With Active Myeloid Malignancies

Author

Matthew P. Connor, Alison W. Loren, Elizabeth O. Hexner, Mary Ellen Martin, Saar I. Gill, Selina M. Luger, James K. Mangan, Alexander E. Perl, Shannon R. McCurdy, Keith W. Pratz, Colleen Timlin, Craig W. Freyer, Alison Carulli, Christopher Catania, Jacqueline Smith, Lauren Hollander, Alexis M. Zebrowski, Edward A. Stadtmauer, David L. Porter, and Noelle V. Frey

Subjects
Transplantation, Molecular Medicine, Immunology and Allergy, Cell Biology, Hematology
Abstract

Patients with refractory or relapsed and refractory myeloid malignancies have a poor prognosis. Allogeneic hematopoietic cell transplantation (HCT) with myeloablative conditioning (MAC) in patients with active, chemotherapy-refractory myeloid disease is historically associated with high rates of relapse and nonrelapse mortality (NRM). A MAC regimen combining clofarabine with busulfan (Clo/Bu4) has been reported to exhibit antileukemic activity with acceptable toxicity in patients age ≤70 years. Here we describe the clinical outcomes of a real-world population of patients with active myeloid malignancies undergoing allogeneic HCT with Clo/Bu4 MAC. In a single-center retrospective descriptive analysis, we identified patients who underwent HCT for myeloid malignancies not in remission using Clo/Bu4 MAC between 2012 and 2020. We report event-free survival (EFS) and overall survival (OS), cumulative incidences of relapse and NRM, and the incidence and severity of acute and chronic graft-versus-host disease (GVHD). We identified 69 patients with a median age of 60 years (range, 22 to 70 years). Most patients had relapsed/refractory or primary refractory acute myelogenous leukemia (AML; n = 55) or refractory myelodysplastic syndrome (MDS; n = 12); 1 patient had chronic myelogenous leukemia, and 1 patient had a blastic plasmacytoid dendritic cell neoplasm. Fifty patients (72.5%) had complete remission at day 100 post-transplantation. Two-year EFS and OS were 30% (95% confidence interval [CI], 20% to 44%) and 40% (95% CI, 29% to 54%), respectively. Patients with AML had a 2-year EFS and OS of 28% (95% CI, 18% to 44%) and 38% (95% CI, 27% to 54%), respectively; those with MDS had a 2-year EFS and OS of 47% (95% CI, 25% to 88%) and 56% (95% CI, 33% to 94%), respectively. The cumulative incidence of relapse at 2 years was 39% (95% CI, 27% to 51%) for all patients, including 45% (95% CI, 31% to 58%) in the patients with AML and 18% (95% CI, 2% to 45%) in those with MDS. NRM at 2 years was 31% (95% CI, 20% to 42%), including 27% (95% CI, 15% to 39%) in patients with AML and 35% (95% CI, 10% to 63%) in those with MDS. The total incidence of acute GVHD (aGVHD) of any severity was 80%, and the incidence of grade III-IV aGVHD was 22%. In patients who achieved remission, those who required systemic immunosuppression for aGVHD (58%) had poorer 2-year EFS (29% versus 54%; P = .05) and 2-year OS (39% versus 70%; P = .04) compared to those who did not. The 2-year cumulative incidence of chronic GVHD was 44% (95% CI, 28% to 58%). Clo/Bu4 MAC followed by allogeneic HCT for patients with active myeloid malignancies is an effective transplantation strategy for patients up to age 70, particularly those with advanced MDS. The high incidence of and poor outcomes associated with aGVHD highlight the importance of optimizing preventative strategies.

Published
2023
Full Text
View/download PDF

24. One versus two sets of busulfan therapeutic drug monitoring in myeloablative allogeneic hematopoietic cell transplant

Author

Chippendale, Lindsey, primary, Freyer, Craig W, additional, Carulli, Alison, additional, Babushok, Daria V, additional, Frey, Noelle V, additional, Gill, Saar I, additional, Hexner, Elizabeth O, additional, Luger, Selina M, additional, Martin, Mary Ellen, additional, Porter, David L, additional, Stadtmauer, Edward A, additional, and Loren, Alison W, additional

Published
2023
Full Text
View/download PDF

25. Fungal Planet Description Sheets: 1478–1549

Author

Crous, P.W., primary, Osieck, E.R., additional, Shivas, R.G., additional, Tan, Y.P., additional, Bishop-Hurley, S.L., additional, Esteve-Raventós, F., additional, Larsson, E., additional, Luangsa-ard, J.J., additional, Pancorbo, F., additional, Balashov, S., additional, Baseia, I.G., additional, Boekhout, T., additional, Chandranayaka, S., additional, Cowan, D.A., additional, Cruz, R.H.S.F., additional, Czachura, P., additional, De la Peña-Lastra, S., additional, Dovana, F., additional, Drury, B., additional, Fell, J., additional, Flakus, A., additional, Fotedar, R., additional, Jurjević, Ž., additional, Kolecka, A., additional, Mack, J., additional, Maggs-Kölling, G., additional, Mahadevakumar, S., additional, Mateos, A., additional, Mongkolsamrit, S., additional, Noisripoom, W., additional, Plaza, M., additional, Overy, D.P., additional, Pitek, M., additional, Sandoval-Denis, M., additional, Vauras, J., additional, Wingfield, M.J., additional, Abell, S.E., additional, Ahmadpour, A., additional, Akulov, A., additional, Alavi, F., additional, Alavi, Z., additional, Altés, A., additional, Alvarado, P., additional, Anand, G., additional, Ashtekar, N., additional, Assyov, B., additional, Banc-Prandi, G., additional, Barbosa, K.D., additional, Barreto, G.G., additional, Bellanger, J.M.., additional, Bezerra, J.L., additional, Bhat, D.J., additional, Bilański, P., additional, Bose, T., additional, Bozok, F., additional, Chaves, J., additional, Costa-Rezende, D.H.., additional, Danteswari, C., additional, Darmostuk, V., additional, Delgado, G., additional, Denman, S., additional, Eichmeier, A., additional, Etayo, J., additional, Eyssartier, G., additional, Faulwetter, S., additional, Ganga, K.G.G.., additional, Ghosta, Y., additional, Goh, J., additional, Góis, J.S., additional, Gramaje, D., additional, Granit, L., additional, Groenewald, M., additional, Gulden, G., additional, Gusmão, L.F.P., additional, Hammerbacher, A., additional, Heidarian, Z., additional, Hywel-Jones, N., additional, Jankowiak, R., additional, Kaliyaperumal, M., additional, Kaygusuz, O., additional, Kezo, K., additional, Khonsanit, A., additional, Kumar, S., additional, Kuo, C.H., additional, Laessøe, T., additional, Latha, K.P.D., additional, Loizides, M., additional, Luo, S.M., additional, Maciá-Vicente, J.G., additional, Manimohan, P., additional, Marbach, P.A.S., additional, Marinho, P., additional, Marney, T.S.., additional, Marques, G., additional, Martín, M.P., additional, Miller, A.N., additional, Mondello, F., additional, Moreno, G., additional, Mufeeda, K.T., additional, Mun, H.Y., additional, Nau, T., additional, Nkomo, T., additional, Okrasińska, A., additional, Oliveira, J.P.A.F., additional, Oliveira, R.L., additional, Ortiz, D.A., additional, Pawłowska, J., additional, Pérez-De-Gregorio, M.`A., additional, Podile, A.R., additional, Portugal, A., additional, Privitera, N., additional, Rajeshkumar, K.C., additional, Rauf, I., additional, Rian, B., additional, Rigueiro-Rodríguez, A., additional, Rivas-Torres, G.F.., additional, Rodriguez-Flakus, P., additional, Romero-Gordillo, M., additional, Saar, I., additional, Saba, M., additional, Santos, C.D.., additional, Sarma, P.V.S.R.N., additional, Siquier, J.L., additional, Sleiman, S., additional, Spetik, M., additional, Sridhar, K.R.., additional, Stryjak-Bogacka, M., additional, Szczepańska, K., additional, Taşikn, H., additional, Tennakoon, D.S., additional, Thanakitpipattana, D., additional, Trovão, J.., additional, Türkekul, A., additional, van Iperen, A.L., additional, van 't Hof, P., additional, Vasquez, G., additional, Visagie, C.M., additional, Wingfield, B.D., additional, Wong, P.T.W., additional, Yang, W.X., additional, Yarar, M., additional, Yarden, O., additional, Yilmaz, N., additional, Zhang, N., additional, Zhu, Y.N., additional, and Groenewald, J.Z.., additional

Published
2023
Full Text
View/download PDF

26. Real‐world effectiveness of intensive chemotherapy with 7&3 versus venetoclax and hypomethylating agent in acute myeloid leukemia

Author

Matthews, Andrew H., primary, Perl, Alexander E., additional, Luger, Selina M., additional, Gill, Saar I., additional, Lai, Catherine, additional, Porter, David L., additional, Skuli, Sarah, additional, Bruno, Ximena Jordan, additional, Carroll, Martin P., additional, Freyer, Craig W., additional, Carulli, Alison, additional, Babushok, Daria V., additional, Frey, Noelle V., additional, Hexner, Elizabeth O., additional, Martin, Mary Ellen, additional, McCurdy, Shannon R., additional, Stadtmauer, Edward A., additional, Loren, Alison W., additional, Paralkar, Vikram R., additional, Maillard, Ivan P., additional, and Pratz, Keith W., additional

Published
2023
Full Text
View/download PDF

28. Fungal Planet description sheets: 1478–1549

Author

Crous, P.W., Osieck, E.R., Shivas, R.G., Tan, Y.P., Bishop-Hurley, S.L., Esteve-Raventós, F., Larsson, E., Luangsa-ard, J.J. (Janet), Pancorbo, F., Balashov, S., Baseia, I.G., Boekhout, T., Chandranayaka, S., Cowan, D.A., Cruz, R.H.S.F., Czachura, P., De la Peña-Lastra, S., Dovana, F., Drury, B., Fell, J., Flakus, A., Fotedar, R., Jurjević, Ž., Kolecka, A., Mack, J., Maggs-Kölling, G., Mahadevakumar, S., Mateos, A., Mongkolsamrit, S., Noisripoom, W., Plaza, M., Overy, D.P., Pitek, M., Sandoval-Denis, M., Vauras, J., Wingfield, M.J., Abell, S.E., Ahmadpour, A., Akulov, A., Alavi, F., Alavi, Z., Altés, A., Alvarado, P., Anand, G., Ashtekar, N., Assyov, B., Banc-Prandi, G., Barbosa, K.D., Barreto, G.G., Bellanger, J.M.., Bezerra, J.L., Bhat, D.J., Bilański, P., Bose, T., Bozok, F., Chaves, J., Costa-Rezende, D.H.., Danteswari, C., Darmostuk, V., Delgado, G., Denman, S., Eichmeier, A., Etayo, J., Eyssartier, G., Faulwetter, S., Ganga, K.G.G.., Ghosta, Y., Goh, J., Góis, J.S., Gramaje, D., Granit, L., Groenewald, M., Gulden, G., Gusmão, L.F.P., Hammerbacher, A., Heidarian, Z., Hywel-Jones, N., Jankowiak, R., Kaliyaperumal, M., Kaygusuz, O., Kezo, K., Khonsanit, A., Kumar, S., Kuo, C.H., Laessøe, T., Latha, K.P.D., Loizides, M., Luo, S.M., Maciá-Vicente, J.G., Manimohan, P., Marbach, P.A.S., Marinho, P., Marney, T.S.., Marques, G., Martín, M.P., Miller, A.N., Mondello, F., Moreno, G., Mufeeda, K.T., Mun, H.Y., Nau, T., Nkomo, T., Okrasińska, A., Oliveira, J.P.A.F., Oliveira, R.L., Ortiz, D.A., Pawłowska, J., Pérez-De-Gregorio, M.`A., Podile, A.R., Portugal, A., Privitera, N., Rajeshkumar, K.C., Rauf, I., Rian, B., Rigueiro-Rodríguez, A., Rivas-Torres, G.F.., Rodriguez-Flakus, P., Romero-Gordillo, M., Saar, I., Saba, M., Santos, C.D.., Sarma, P.V.S.R.N., Siquier, J.L., Sleiman, S., Spetik, M., Sridhar, K.R.., Stryjak-Bogacka, M., Szczepańska, K., Taşikn, H., Tennakoon, D.S., Thanakitpipattana, D., Trovão, J.., Türkekul, A., van Iperen, A.L., van 't Hof, P., Vasquez, G., Visagie, C.M., Wingfield, B.D., Wong, P.T.W., Yang, W.X., Yarar, M., Yarden, O., Yilmaz, N., Zhang, N., Zhu, Y.N., Groenewald, J.Z., Crous, P.W., Osieck, E.R., Shivas, R.G., Tan, Y.P., Bishop-Hurley, S.L., Esteve-Raventós, F., Larsson, E., Luangsa-ard, J.J. (Janet), Pancorbo, F., Balashov, S., Baseia, I.G., Boekhout, T., Chandranayaka, S., Cowan, D.A., Cruz, R.H.S.F., Czachura, P., De la Peña-Lastra, S., Dovana, F., Drury, B., Fell, J., Flakus, A., Fotedar, R., Jurjević, Ž., Kolecka, A., Mack, J., Maggs-Kölling, G., Mahadevakumar, S., Mateos, A., Mongkolsamrit, S., Noisripoom, W., Plaza, M., Overy, D.P., Pitek, M., Sandoval-Denis, M., Vauras, J., Wingfield, M.J., Abell, S.E., Ahmadpour, A., Akulov, A., Alavi, F., Alavi, Z., Altés, A., Alvarado, P., Anand, G., Ashtekar, N., Assyov, B., Banc-Prandi, G., Barbosa, K.D., Barreto, G.G., Bellanger, J.M.., Bezerra, J.L., Bhat, D.J., Bilański, P., Bose, T., Bozok, F., Chaves, J., Costa-Rezende, D.H.., Danteswari, C., Darmostuk, V., Delgado, G., Denman, S., Eichmeier, A., Etayo, J., Eyssartier, G., Faulwetter, S., Ganga, K.G.G.., Ghosta, Y., Goh, J., Góis, J.S., Gramaje, D., Granit, L., Groenewald, M., Gulden, G., Gusmão, L.F.P., Hammerbacher, A., Heidarian, Z., Hywel-Jones, N., Jankowiak, R., Kaliyaperumal, M., Kaygusuz, O., Kezo, K., Khonsanit, A., Kumar, S., Kuo, C.H., Laessøe, T., Latha, K.P.D., Loizides, M., Luo, S.M., Maciá-Vicente, J.G., Manimohan, P., Marbach, P.A.S., Marinho, P., Marney, T.S.., Marques, G., Martín, M.P., Miller, A.N., Mondello, F., Moreno, G., Mufeeda, K.T., Mun, H.Y., Nau, T., Nkomo, T., Okrasińska, A., Oliveira, J.P.A.F., Oliveira, R.L., Ortiz, D.A., Pawłowska, J., Pérez-De-Gregorio, M.`A., Podile, A.R., Portugal, A., Privitera, N., Rajeshkumar, K.C., Rauf, I., Rian, B., Rigueiro-Rodríguez, A., Rivas-Torres, G.F.., Rodriguez-Flakus, P., Romero-Gordillo, M., Saar, I., Saba, M., Santos, C.D.., Sarma, P.V.S.R.N., Siquier, J.L., Sleiman, S., Spetik, M., Sridhar, K.R.., Stryjak-Bogacka, M., Szczepańska, K., Taşikn, H., Tennakoon, D.S., Thanakitpipattana, D., Trovão, J.., Türkekul, A., van Iperen, A.L., van 't Hof, P., Vasquez, G., Visagie, C.M., Wingfield, B.D., Wong, P.T.W., Yang, W.X., Yarar, M., Yarden, O., Yilmaz, N., Zhang, N., Zhu, Y.N., and Groenewald, J.Z.

Abstract

Novel species of fungi described in this study include those from various countries as follows: Australia, Aschersonia mackerrasiae on whitefly, Cladosporium corticola on bark of Melaleuca quinquenervia, Penicillium nudgee from soil under Melaleuca quinquenervia, Pseudocercospora blackwoodiae on leaf spot of Persoonia falcata, and Pseudocercospora dalyelliae on leaf spot of Senna alata. Bolivia, Aspicilia lutzoniana on fully submersed siliceous schist in high-mountain streams, and Niesslia parviseta on the lower part and apothecial discs of Erioderma barbellatum onatwig. Brazil, Cyathus bonsai on decaying wood, Geastrum albofibrosum from moist soil with leaf litter, Laetiporus pratigiensis on a trunk of a living unknown hardwood tree species, and Scytalidium synnematicum on dead twigs of unidentified plant. Bulgaria, Amanita abscondita on sandy soil in a plantation of Quercus suber. Canada, Penicillium acericola on dead bark of Acer saccharum, and Penicillium corticola on dead bark of Acer saccharum. China, Colletotrichum qingyuanense on fruit lesion of Capsicum annuum. Denmark, Helminthosphaeria leptospora on corticioid Neohypochnicium cremicolor. Ecuador (Galapagos), Phaeosphaeria scalesiae on Scalesia sp. Finland, Inocybe jacobssonii on calcareouss oils in dry forests and park habitats. France, Cortinarius rufomyrrheus on sandy soil under Pinus pinaster, and Periconia neominutissima on leaves of Poaceae. India, Coprinopsis fragilis on decaying bark of logs, Filoboletus keralensis on unidentified woody substrate, Penicillium sankaranii from soil, Physisporinus tamilnaduensis on the trunk of Azadirachta indica, and Poronia nagaraholensis on elephant dung. Iran, Neosetophoma fic on infected leaves of Ficus elastica. Israel, Cnidariophoma eilatica (incl. Cnidariophoma gen. nov.) from Stylophora pistillata. Italy, Lyophyllum obscurum on acidic soil. Namibia, Aureobasidium faidherbiae on dead leaf of Faidherbia albida, and Aureobasidium welwitschiae on dead leaves of W

Published
2023
Full Text
View/download PDF

29. Fungal Planet description sheets:1478–1549

Author

Crous, P. W., Osieck, E. R., Shivas, R. G., Tan, Y. P., Bishop-Hurley, S. L., Esteve-Raventós, F., Larsson, E., Luangsa-ard, J. J., Pancorbo, F., Balashov, S., Baseia, I. G., Boekhout, T., Chandranayaka, S., Cowan, D. A., Cruz, R. H. S. F., Czachura, P., De la Peña-Lastra, S., Dovana, F., Drury, B., Fell, J., Flakus, A., Fotedar, R., Jurjević, Ž., Kolecka, A., Mack, J., Maggs-Kölling, G., Mahadevakumar, S., Mateos, A., Mongkolsamrit, S., Noisripoom, W., Plaza, M., Overy, D. P., Piątek, M., Sandoval-Denis, M., Vauras, J., Wingfield, M. J., Abell, S. E., Ahmadpour, A., Akulov, A., Alavi, F., Alavi, Z., Altés, A., Alvarado, P., Anand, G., Ashtekar, N., Assyov, B., Banc-Prandi, G., Barbosa, K. D., Barreto, G. G., Bellanger, J.-M., Bezerra, J. L., Bhat, D. J., Bilański, P., Bose, T., Bozok, F., Chaves, J., Costa-Rezende, D. H., Danteswari, C., Darmostuk, V., Delgado, G., Denman, S., Eichmeier, A., Etayo, J., Eyssartier, G., Faulwetter, S., Ganga, K. G. G., Ghosta, Y., Goh, J., Góis, J. S., Gramaje, D., Granit, L., Groenewald, M., Gulden, G., Gusmão, L. F. P., Hammerbacher, A., Heidarian, Z., Hywel-Jones, N., Jankowiak, R., Kaliyaperumal, M., Kaygusuz, O., Kezo, K., Khonsanit, A., Kumar, S., Kuo, C. H., Læssøe, T., Latha, K. P. D., Loizides, M., Luo, S. M., Maciá-Vicente, J. G., Manimohan, P., Marbach, P. A. S., Marinho, P., Marney, T. S., Marques, G., Martín, M. P., Miller, A. N., Mondello, F., Moreno, G., Mufeeda, K. T., Mun, H. Y., Nau, T., Nkomo, T., Okrasińska, A., Oliveira, J. P. A. F., Oliveira, R. L., Ortiz, D. A., Pawłowska, J., Pérez-De-gregorio, M., Podile, A. R., Portugal, A., Privitera, N., Rajeshkumar, K. C., Rauf, I., Rian, B., Rigueiro-Rodríguez, A., Rivas-Torres, G. F., Rodriguez-Flakus, P., Romero-Gordillo, M., Saar, I., Saba, M., Santos, C. D., Sarma, P. V. S. R. N., Siquier, J. L., Sleiman, S., Spetik, M., Sridhar, K. R., Stryjak-Bogacka, M., Szczepańska, K., Taşkın, H., Tennakoon, D. S., Thanakitpipattana, D., Trovão, J., Türkekul, I, van Iperen, A. L., van 't Hof, P., Vasquez, G., Visagie, C. M., Wingfield, B. D., Wong, P. T. W., Yang, W. X., Yarar, M., Yarden, O., Yilmaz, N., Zhang, N., Zhu, Y. N., Groenewald, J. Z., Crous, P. W., Osieck, E. R., Shivas, R. G., Tan, Y. P., Bishop-Hurley, S. L., Esteve-Raventós, F., Larsson, E., Luangsa-ard, J. J., Pancorbo, F., Balashov, S., Baseia, I. G., Boekhout, T., Chandranayaka, S., Cowan, D. A., Cruz, R. H. S. F., Czachura, P., De la Peña-Lastra, S., Dovana, F., Drury, B., Fell, J., Flakus, A., Fotedar, R., Jurjević, Ž., Kolecka, A., Mack, J., Maggs-Kölling, G., Mahadevakumar, S., Mateos, A., Mongkolsamrit, S., Noisripoom, W., Plaza, M., Overy, D. P., Piątek, M., Sandoval-Denis, M., Vauras, J., Wingfield, M. J., Abell, S. E., Ahmadpour, A., Akulov, A., Alavi, F., Alavi, Z., Altés, A., Alvarado, P., Anand, G., Ashtekar, N., Assyov, B., Banc-Prandi, G., Barbosa, K. D., Barreto, G. G., Bellanger, J.-M., Bezerra, J. L., Bhat, D. J., Bilański, P., Bose, T., Bozok, F., Chaves, J., Costa-Rezende, D. H., Danteswari, C., Darmostuk, V., Delgado, G., Denman, S., Eichmeier, A., Etayo, J., Eyssartier, G., Faulwetter, S., Ganga, K. G. G., Ghosta, Y., Goh, J., Góis, J. S., Gramaje, D., Granit, L., Groenewald, M., Gulden, G., Gusmão, L. F. P., Hammerbacher, A., Heidarian, Z., Hywel-Jones, N., Jankowiak, R., Kaliyaperumal, M., Kaygusuz, O., Kezo, K., Khonsanit, A., Kumar, S., Kuo, C. H., Læssøe, T., Latha, K. P. D., Loizides, M., Luo, S. M., Maciá-Vicente, J. G., Manimohan, P., Marbach, P. A. S., Marinho, P., Marney, T. S., Marques, G., Martín, M. P., Miller, A. N., Mondello, F., Moreno, G., Mufeeda, K. T., Mun, H. Y., Nau, T., Nkomo, T., Okrasińska, A., Oliveira, J. P. A. F., Oliveira, R. L., Ortiz, D. A., Pawłowska, J., Pérez-De-gregorio, M., Podile, A. R., Portugal, A., Privitera, N., Rajeshkumar, K. C., Rauf, I., Rian, B., Rigueiro-Rodríguez, A., Rivas-Torres, G. F., Rodriguez-Flakus, P., Romero-Gordillo, M., Saar, I., Saba, M., Santos, C. D., Sarma, P. V. S. R. N., Siquier, J. L., Sleiman, S., Spetik, M., Sridhar, K. R., Stryjak-Bogacka, M., Szczepańska, K., Taşkın, H., Tennakoon, D. S., Thanakitpipattana, D., Trovão, J., Türkekul, I, van Iperen, A. L., van 't Hof, P., Vasquez, G., Visagie, C. M., Wingfield, B. D., Wong, P. T. W., Yang, W. X., Yarar, M., Yarden, O., Yilmaz, N., Zhang, N., Zhu, Y. N., and Groenewald, J. Z.

Abstract

Novel species of fungi described in this study include those from various countries as follows: Australia, Aschersonia mackerrasiae on whitefly, Cladosporium corticola on bark of Melaleuca quinquenervia, Penicillium nudgee from soil under Melaleuca quinquenervia, Pseudocercospora blackwoodiae on leaf spot of Persoonia falcata, and Pseudocercospora dalyelliae on leaf spot of Senna alata. Bolivia, Aspicilia lutzoniana on fully submersed siliceous schist in high-mountain streams, and Niesslia parviseta on the lower part and apothecial discs of Erioderma barbellatum onatwig. Brazil, Cyathus bonsai on decaying wood, Geastrum albofibrosum from moist soil with leaf litter, Laetiporus pratigiensis on a trunk of a living unknown hardwood tree species, and Scytalidium synnematicum on dead twigs of unidentified plant. Bulgaria, Amanita abscondita on sandy soil in a plantation of Quercus suber. Canada, Penicillium acericola on dead bark of Acer saccharum, and Penicillium corticola on dead bark of Acer saccharum. China, Colletotrichum qingyuanense on fruit lesion of Capsicum annuum. Denmark, Helminthosphaeria leptospora on corticioid Neohypochnicium cremicolor. Ecuador (Galapagos), Phaeosphaeria scalesiae on Scalesia sp. Finland, Inocybe jacobssonii on calcareouss oils in dry forests and park habitats. France, Cortinarius rufomyrrheus on sandy soil under Pinus pinaster, and Periconia neominutissima on leaves of Poaceae. India, Coprinopsis fragilis on decaying bark of logs, Filoboletus keralensis on unidentified woody substrate, Penicillium sankaranii from soil, Physisporinus tamilnaduensis on the trunk of Azadirachta indica, and Poronia nagaraholensis on elephant dung. Iran, Neosetophoma fic on infected leaves of Ficus elastica. Israel, Cnidariophoma eilatica (incl. Cnidariophoma gen. nov.) from Stylophora pistillata. Italy, Lyophyllum obscurum on acidic soil. Namibia, Aureobasidium faidherbiae on dead leaf of Faidherbia albida, and Aureobasidium welwitschiae on dead leaves o

Published
2023

30. Characterization of the calcineurin inhibitor pain syndrome in patients undergoing allogeneic hematopoietic cell transplantation.

Author

Freyer, Craig W., Carulli, Alison, Frey, Noelle V., Gill, Saar I., Hexner, Elizabeth O., Martin, Mary Ellen, Luger, Selina M., Porter, David L., Stadtmauer, Edward A., and Loren, Alison W.

Subjects
HEMATOPOIETIC stem cell transplantation, CALCINEURIN, LEG pain, TOTAL body irradiation, CALCIUM antagonists
Abstract

Calcineurin inhibitor pain syndrome (CIPS) is a rare complication of graft-vs-host disease prophylaxis following allogeneic hematopoietic cell transplant (alloHCT). CIPS presents as severe bilateral lower extremity pain, and the incidence, risk factors, and management of CIPS are poorly characterized. This is a single center retrospective study of patients who received tacrolimus (TAC) following alloHCT to describe the characteristics and management of CIPS and compare to a cohort who did not develop CIPS. Fifteen of 585 alloHCT patients (2.6%) developed CIPS at a median of 5 days following TAC initiation and a median level of 10.5 ng/mL. Severe bilateral foot, ankle, or leg pain were the primary symptoms. Patients with CIPS were younger and more frequently received myeloablative conditioning and total body irradiation compared to patients without CIPS. Analgesic regimens included dihydropyridine calcium channel blockers, gabapentinoids, topical diclofenac, and opioids. Clinicians should be aware of this uncommon but severe adverse effect. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

31. CD38 as a pan-hematologic target for chimeric antigen receptor T cells

Author

Glisovic-Aplenc, Tina, primary, Diorio, Caroline, additional, Chukinas, John A, additional, Veliz, Kimberly, additional, Shestova, Olga, additional, Shen, Feng, additional, Nunez-Cruz, Selene, additional, Vincent, Tiffaney L, additional, Miao, Fei, additional, Milone, Michael C, additional, June, Carl H, additional, Teachey, David T, additional, Tasian, Sarah K, additional, Aplenc, Richard, additional, and Gill, Saar I., additional

Published
2023
Full Text
View/download PDF

32. Venetoclax in combination with hypomethylating agents or low dose cytarabine for relapsed and refractory acute myeloid leukemia

Author

Molly E. Graveno, Alison Carulli, Craig W. Freyer, Brendan L. Mangan, Robert Nietupski, Alison W. Loren, Noelle V. Frey, David L. Porter, Saar I. Gill, Elizabeth O. Hexner, Selina M. Luger, Mary Ellen Martin, Shannon R. McCurdy, Alexander E. Perl, Daria V. Babushok, and Keith W. Pratz

Subjects
Leukemia, Myeloid, Acute, Sulfonamides, Cancer Research, Oncology, Antineoplastic Combined Chemotherapy Protocols, Cytarabine, Humans, Hematology, Bridged Bicyclo Compounds, Heterocyclic, Retrospective Studies
Abstract

Limited treatment options exist for patients with relapsed/refractory (R/R) acute myeloid leukemia (AML). Venetoclax (VEN) in combination with a hypomethylating agent (HMA) or low-dose cytarabine (LDAC) has been recently approved for treatment-naïve patients unfit for intensive induction. Limited data are available to characterize the efficacy of VEN combinations in R/R AML. We retrospectively analyzed 77 patients with a median of 1 prior therapy (range 0-5) treated with VEN combinations for R/R AML or AML secondary to myelodysplastic syndrome (MDS) progressing after HMA monotherapy. The median overall survival (OS) was 13.1 months (95% CI 9.2-15.1). The median progression-free survival (PFS) was 12 months (95% CI 8.2-15.4) with a median duration of response of 8.9 months (95% CI 5.7-13.9). Overall response rate (ORR) was 68% with a composite complete response (CR) and CR with incomplete hematologic recovery (CRi) rate of 53%. VEN combination therapy is efficacious in R/R AML and further prospective studies are warranted.

Published
2022
Full Text
View/download PDF

33. CD38 as a pan-hematologic target for chimeric antigen receptor T cells

Author

Tina Glisovic-Aplenc, Caroline Diorio, John A Chukinas, Kimberly Veliz, Olga Shestova, Feng Shen, Selene Nunez-Cruz, Tiffaney L Vincent, Fei Miao, Michael C Milone, Carl H June, David T Teachey, Sarah K Tasian, Richard Aplenc, and Saar I. Gill

Subjects
Hematology
Abstract

Many patients with hematologic malignancies are not curable with chemotherapy and require novel therapeutic approaches. Chimeric antigen receptor (CAR) T cell therapy is one such approach that involves the transfer of T cells engineered to express CARs for a specific cell-surface antigen. CD38 is a validated tumor antigen in multiple myeloma (MM) and in T-cell acute lymphoblastic leukemia (T-ALL) and is also overexpressed in acute myeloid leukemia (AML). Here, we developed human CD38-redirected T cells (CART-38) as a unified approach to treat three different hematologic malignancies that occur across the pediatric-to-adult age spectrum. Importantly, CD38 expression on activated T cells did not impair CART-38 cells expansion or in vitro function. In xenografted mice, CART-38-mediated rejection of AML, T-ALL, and MM cell lines and primary samples and prolonged survival. In a xenograft model of normal human hematopoiesis, CART-38 resulted in the expected reduction of hematopoietic progenitors, which warrants caution and careful monitoring of this potential toxicity when translating this new immunotherapy into the clinic. Deploying CART-38 against multiple CD38-expressing malignancies is significant, as it expands the potential for this novel therapy to impact diverse patient populations.

Published
2023
Full Text
View/download PDF

34. Day 4 vs. day 12 G-CSF administration following reduced intensity peripheral blood allogeneic stem cell transplant

Author

Rachel V. Hatch, Craig W. Freyer, Alison Carulli, Gretchen Redline, Daria V. Babushok, Noelle V. Frey, Saar I. Gill, Elizabeth O. Hexner, Selina M. Luger, Mary Ellen Martin, Shannon R. McCurdy, Alexander E. Perl, David L. Porter, Keith W. Pratz, Edward A. Stadtmauer, and Alison W. Loren

Subjects
Mucositis, Methotrexate, Oncology, Granulocyte Colony-Stimulating Factor, Hematopoietic Stem Cell Transplantation, Graft vs Host Disease, Humans, Transplantation, Homologous, Pharmacology (medical), Bone Marrow Transplantation, Retrospective Studies
Abstract

Introduction Granulocyte colony-stimulating factor (G-CSF) hastens neutrophil engraftment and reduces infections after allogeneic hematopoietic cell transplant (alloHCT), yet the optimal start date is unknown. Additionally, concurrent G-CSF and methotrexate for graft-vs-host disease (GVHD) prophylaxis may potentiate myelosuppression, and prolonged G-CSF is costly. Our institution changed from day + 4 to day + 12 G-CSF initiation following reduced intensity (RIC) alloHCT with methotrexate GVHD prophylaxis. Methods We retrospectively compared day + 4 and day + 12 G-CSF initiation after RIC alloHCT from 2017–2021. The primary endpoint was the time to neutrophil engraftment. Secondary endpoints included length of stay (LOS) and the time to platelet engraftment as well as the incidence of infectious events, acute GVHD (aGVHD), and mucositis. Results Thirty-two patients were included in each group with similar baseline characteristics. We observed faster neutrophil engraftment (median 12 vs. 15 days, p = 0.01) and platelet engraftment (median 13 vs. 15 days, p = 0.026) with day + 4 vs. day + 12 G-CSF initiation. Median LOS was 23 days (range, 19–32) with day + 4 initiation vs. 24 days (21–30) with day + 12 (p = 0.046). The incidence of culture-negative febrile neutropenia (p = 0.12), any grade aGVHD (p = 0.58), and grade 2-4 mucositis (p = 0.8) were similar between groups. Conclusion Compared to day + 4, day + 12 G-CSF initiation following RIC alloHCT had a longer time to neutrophil and platelet engraftment. Day + 12 initiation also resulted in longer LOS, which while statistically significant, was potentially of limited clinical significance. These findings are hypothesis generating.

Published
2022
Full Text
View/download PDF

35. Letermovir vs. high-dose valacyclovir for cytomegalovirus prophylaxis following haploidentical or mismatched unrelated donor allogeneic hematopoietic cell transplantation receiving post-transplant cyclophosphamide

Author

Craig W. Freyer, Alison Carulli, Shannon Gier, Alex Ganetsky, Colleen Timlin, Mindy Schuster, Daria Babushok, Noelle V. Frey, Saar I. Gill, Elizabeth O. Hexner, Selina M. Luger, James K. Mangan, Mary Ellen Martin, Shannon R. McCurdy, Alexander E. Perl, David L. Porter, Keith Pratz, Jacqueline Smith, Edward A. Stadtmauer, and Alison W. Loren

Subjects
Adult, Cancer Research, Hematopoietic Stem Cell Transplantation, Cytomegalovirus, Graft vs Host Disease, Hematology, Acetates, Oncology, Valacyclovir, Cytomegalovirus Infections, Quinazolines, Humans, Unrelated Donors, Cyclophosphamide, Retrospective Studies
Abstract

Patients undergoing haploidentical or mismatched unrelated donor (haplo/MMUD) allogeneic hematopoietic cell transplantation (alloHCT) receiving post-transplant cyclophosphamide (PTCy) are at high risk of cytomegalovirus (CMV) infection. Experience with letermovir (LET) in this population is limited. This single center retrospective cohort study compared CMV and transplant outcomes between LET and a historical control with high-dose valacyclovir (HDV) prophylaxis in adults undergoing haplo/MMUD alloHCT. Thirty-eight CMV seropositive patients were included, 19 in each arm. LET reduced the incidence of CMV infection (5% vs. 53%, RR 0.01, 95% CI 0.014-0.71

Published
2022
Full Text
View/download PDF

36. Clofarabine and Busulfan Myeloablative Conditioning in Allogeneic Hematopoietic Cell Transplantation for Patients With Active Myeloid Malignancies

Author

Connor, Matthew P., primary, Loren, Alison W., additional, Hexner, Elizabeth O., additional, Martin, Mary Ellen, additional, Gill, Saar I., additional, Luger, Selina M., additional, Mangan, James K., additional, Perl, Alexander E., additional, McCurdy, Shannon R., additional, Pratz, Keith W., additional, Timlin, Colleen, additional, Freyer, Craig W., additional, Carulli, Alison, additional, Catania, Christopher, additional, Smith, Jacqueline, additional, Hollander, Lauren, additional, Zebrowski, Alexis M., additional, Stadtmauer, Edward A., additional, Porter, David L., additional, and Frey, Noelle V., additional

Published
2023
Full Text
View/download PDF

37. Author Correction: Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy

Author

Smith, Melody, primary, Dai, Anqi, additional, Ghilardi, Guido, additional, Amelsberg, Kimberly V., additional, Devlin, Sean M., additional, Pajarillo, Raymone, additional, Slingerland, John B., additional, Beghi, Silvia, additional, Herrera, Pamela S., additional, Giardina, Paul, additional, Clurman, Annelie, additional, Dwomoh, Emmanuel, additional, Armijo, Gabriel, additional, Gomes, Antonio L. C., additional, Littmann, Eric R., additional, Schluter, Jonas, additional, Fontana, Emily, additional, Taur, Ying, additional, Park, Jae H., additional, Palomba, Maria Lia, additional, Halton, Elizabeth, additional, Ruiz, Josel, additional, Jain, Tania, additional, Pennisi, Martina, additional, Afuye, Aishat Olaide, additional, Perales, Miguel-Angel, additional, Freyer, Craig W., additional, Garfall, Alfred, additional, Gier, Shannon, additional, Nasta, Sunita, additional, Landsburg, Daniel, additional, Gerson, James, additional, Svoboda, Jakub, additional, Cross, Justin, additional, Chong, Elise A., additional, Giralt, Sergio, additional, Gill, Saar I., additional, Riviere, Isabelle, additional, Porter, David L., additional, Schuster, Stephen J., additional, Sadelain, Michel, additional, Frey, Noelle, additional, Brentjens, Renier J., additional, June, Carl H., additional, Pamer, Eric G., additional, Peled, Jonathan U., additional, Facciabene, Andrea, additional, van den Brink, Marcel R. M., additional, and Ruella, Marco, additional

Published
2022
Full Text
View/download PDF

38. Abstract 561: CAR-targeted IL-2 drives selective CAR-T cell expansion and improves anti-tumor efficacy

Author

Mathewson, Nathan D., primary, Moynihan, Kelly D., additional, Sleiman, Sara, additional, Chen, Wei, additional, Bessette, Paul, additional, Kimberlin, Christopher, additional, Wigton, Eric, additional, Pappas, Danielle, additional, Park, Terrence, additional, Schumacher, Ton N., additional, Gill, Saar I., additional, Yeung, Yik Andy, additional, and Djuretic, Ivana, additional

Published
2022
Full Text
View/download PDF

42. Venetoclax in combination with hypomethylating agents or low dose cytarabine for relapsed and refractory acute myeloid leukemia

Author

Graveno, Molly E., primary, Carulli, Alison, additional, Freyer, Craig W., additional, Mangan, Brendan L., additional, Nietupski, Robert, additional, Loren, Alison W., additional, Frey, Noelle V., additional, Porter, David L., additional, Gill, Saar I., additional, Hexner, Elizabeth O., additional, Luger, Selina M., additional, Martin, Mary Ellen, additional, McCurdy, Shannon R., additional, Perl, Alexander E., additional, Babushok, Daria V., additional, and Pratz, Keith W., additional

Published
2022
Full Text
View/download PDF

43. Day 4 vs. day 12 G-CSF administration following reduced intensity peripheral blood allogeneic stem cell transplant

Author

Hatch, Rachel V., primary, Freyer, Craig W., additional, Carulli, Alison, additional, Redline, Gretchen, additional, Babushok, Daria V., additional, Frey, Noelle V., additional, Gill, Saar I., additional, Hexner, Elizabeth O., additional, Luger, Selina M., additional, Martin, Mary Ellen, additional, McCurdy, Shannon R., additional, Perl, Alexander E., additional, Porter, David L., additional, Pratz, Keith W., additional, Stadtmauer, Edward A., additional, and Loren, Alison W., additional

Published
2022
Full Text
View/download PDF

44. Letermovir vs. high-dose valacyclovir for cytomegalovirus prophylaxis following haploidentical or mismatched unrelated donor allogeneic hematopoietic cell transplantation receiving post-transplant cyclophosphamide

Author

Freyer, Craig W., primary, Carulli, Alison, additional, Gier, Shannon, additional, Ganetsky, Alex, additional, Timlin, Colleen, additional, Schuster, Mindy, additional, Babushok, Daria, additional, Frey, Noelle V., additional, Gill, Saar I., additional, Hexner, Elizabeth O., additional, Luger, Selina M., additional, Mangan, James K., additional, Martin, Mary Ellen, additional, McCurdy, Shannon R., additional, Perl, Alexander E., additional, Porter, David L., additional, Pratz, Keith, additional, Smith, Jacqueline, additional, Stadtmauer, Edward A., additional, and Loren, Alison W., additional

Published
2022
Full Text
View/download PDF

45. Interim Results of a Phase I/II Study of Intermediate-Dose Post-Transplantation Cyclophosphamide after Reduced Intensity Conditioned HLA-Matched Bone Marrow Transplantation for Older or Infirm Patients

Author

Hyder, Mustafa A., McCurdy, Shannon R., Sabina, Ruby, DeVries, Ashley, Chalupa, Kirstin, Berryman, Natasha, Bernhardt, Jessica, Cusmano, Alison Christina, Chai, Amy, Schwartz, Rebecca, Dimitrova, Dimana, Rechache, Kamil, McKeown, Christi, Stokes, Anita, Sponaugle, Jennifer, Frey, Noelle V., Gill, Saar I., Hexner, Elizabeth O, Martin, Mary Ellen, Hossain, Nasheed, Porter, David L., Loren, Alison W., Kanakry, Jennifer A., and Kanakry, Christopher G.

Published
2024
Full Text
View/download PDF

46. Abstract 561: CAR-targeted IL-2 drives selective CAR-T cell expansion and improves anti-tumor efficacy

Author

Nathan D. Mathewson, Kelly D. Moynihan, Sara Sleiman, Wei Chen, Paul Bessette, Christopher Kimberlin, Eric Wigton, Danielle Pappas, Terrence Park, Ton N. Schumacher, Saar I. Gill, Yik Andy Yeung, and Ivana Djuretic

Subjects
Cancer Research, Oncology
Abstract

Chimeric antigen receptor T cell (CAR-T) therapies have transformed the treatment of some hematological malignancies and are showing promising preliminary results in solid tumors. Recent studies have shown that in vivo expansion and persistence of CAR-Ts are correlated with improved therapeutic outcomes in patients. Administration of IL-2 enhances CAR-T engraftment, persistence, and functionality in preclinical models. However, the clinical potential of IL-2 stimulation with cell therapies is limited using current molecules due to severe toxicity of high-dose IL-2 and the inadequate selectivity of existing engineered IL-2 variants which expand multiple endogenous cells in addition to CAR-T cells. To address this challenge, we have applied our cis-targeting technology to develop CAR-T selective IL-2 fusion molecules that specifically activate CAR-Ts, while exhibiting minimal activity on CAR-negative cells. Cis-targeted IL-2 fusions are comprised of a fusion between a targeting antibody and an IL-2 mutein having attenuated binding to IL2R⍺ and IL2Rβ. The attenuated cytokine selectively binds and activates IL-2 receptors on CAR-Ts via the avidity provided by the targeting arm. We engineered two cis-targeted CAR-T selective IL-2 fusions, CAR-IL2 or EGFRt-IL2. CAR-IL2 targets the FMC63 CAR directly without blocking CD19 antigen recognition, enabling targeting of approved anti-CD19 CAR-T products, and EGFRt-IL2 targets the EGFRt tag co-expressed with the CAR. Molecules were characterized in vitro using primary human CAR-transduced T cells. The in vivo activity was examined using tumor bearing NSG mice infused with human CAR-Ts. The specificity of the CAR-IL2 or EGFRt-IL2 molecules was demonstrated by their ability to selectively induce pSTAT5 signaling resulting in >1000-fold preferential STAT5 activity in CAR-expressing cells compared to CAR-negative cells. The ability of the fusion proteins to selectively expand CAR-Ts in vivo was shown through a substantial and specific expansion of the infused CAR-Ts. The CAR-T fraction increased from approximately 50% of infused T cells, to over 93% of T cells, demonstrating a nearly 40-fold expansion in vivo. Re-expansion of CAR-Ts was demonstrated after allowing the CAR-Ts to rest in vivo >100 days; re-dosing resulted in significant and selective re-expansion of CAR-T cells. Furthermore, treatment with the CAR-IL2 molecule enhanced tumor regression of CD19+ lymphoma-bearing mice infused with suboptimal doses of CAR-Ts. Together, these data demonstrate that our cis-targeted IL-2 molecules selectively activate CAR-Ts in vitro and enhance CAR-T expansion and anti-tumor efficacy in vivo. Cis-targeted IL-2 fusion molecules directed by anti-CAR or anti-tag antibodies represent a promising approach to confer enhanced CAR-T activity in a specific and temporally controlled manner. Citation Format: Nathan D. Mathewson, Kelly D. Moynihan, Sara Sleiman, Wei Chen, Paul Bessette, Christopher Kimberlin, Eric Wigton, Danielle Pappas, Terrence Park, Ton N. Schumacher, Saar I. Gill, Yik Andy Yeung, Ivana Djuretic. CAR-targeted IL-2 drives selective CAR-T cell expansion and improves anti-tumor efficacy [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 561.

Published
2022
Full Text
View/download PDF

47. Decade-long leukaemia remissions with persistence of CD4+ CAR T cells.

Author

Melenhorst, J. Joseph, Chen, Gregory M., Wang, Meng, Porter, David L., Chen, Changya, Collins, McKensie A., Gao, Peng, Bandyopadhyay, Shovik, Sun, Hongxing, Zhao, Ziran, Lundh, Stefan, Pruteanu-Malinici, Iulian, Nobles, Christopher L., Maji, Sayantan, Frey, Noelle V., Gill, Saar I., Tian, Lifeng, Kulikovskaya, Irina, Gupta, Minnal, and Ambrose, David E.

Abstract

The adoptive transfer of T lymphocytes reprogrammed to target tumour cells has demonstrated potential for treatment of various cancers1–7. However, little is known about the long-term potential and clonal stability of the infused cells. Here we studied long-lasting CD19-redirected chimeric antigen receptor (CAR) T cells in two patients with chronic lymphocytic leukaemia1–4 who achieved a complete remission in 2010. CAR T cells remained detectable more than ten years after infusion, with sustained remission in both patients. Notably, a highly activated CD4+ population emerged in both patients, dominating the CAR T cell population at the later time points. This transition was reflected in the stabilization of the clonal make-up of CAR T cells with a repertoire dominated by a small number of clones. Single-cell profiling demonstrated that these long-persisting CD4+ CAR T cells exhibited cytotoxic characteristics along with ongoing functional activation and proliferation. In addition, longitudinal profiling revealed a population of gamma delta CAR T cells that prominently expanded in one patient concomitant with CD8+ CAR T cells during the initial response phase. Our identification and characterization of these unexpected CAR T cell populations provide novel insight into the CAR T cell characteristics associated with anti-cancer response and long-term remission in leukaemia.Infusion of CD19-directed chimeric antigen receptor T cells into two patients with chronic lymphocytic leukaemia resulted in complete tumour remission and persistence of the infused cells more than ten years later. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

48. Author Correction: Decade-long leukaemia remissions with persistence of CD4+CAR T cells

Author

Melenhorst, J. Joseph, Chen, Gregory M., Wang, Meng, Porter, David L., Chen, Changya, Collins, McKensie A., Gao, Peng, Bandyopadhyay, Shovik, Sun, Hongxing, Zhao, Ziran, Lundh, Stefan, Pruteanu-Malinici, Iulian, Nobles, Christopher L., Maji, Sayantan, Frey, Noelle V., Gill, Saar I., Loren, Alison W., Tian, Lifeng, Kulikovskaya, Irina, Gupta, Minnal, Ambrose, David E., Davis, Megan M., Fraietta, Joseph A., Brogdon, Jennifer L., Young, Regina M., Chew, Anne, Levine, Bruce L., Siegel, Donald L., Alanio, Cécile, Wherry, E. John, Bushman, Frederic D., Lacey, Simon F., Tan, Kai, and June, Carl H.

Published
2022
Full Text
View/download PDF

49. 10 Safety and efficacy of nebulized phage in people with cystic fibrosis with chronic Pseudomonas aeruginosa pulmonary infection: A phase 1b/2a randomized, double-blind, placebo-controlled, multicenter study.

Author

Rappo, U., Maimon, I., Cohen, A., Kario, E., Gold, J., Nevenzal, H., Saar, I. Levy, Cohen, T., Weiner, I., Livnat, H. Sberro, Slutskin, I. Vainberg, Jablonska, J., Mordoch, R., Axelrod, T., Bahar, O., Buchshtab, N., Lev, V., Tzur, Y., Zarchin, Y., and Golembo, M.

Subjects
*PSEUDOMONAS aeruginosa infections, *CYSTIC fibrosis, *BACTERIOPHAGES
Published
2024
Full Text
View/download PDF

50. Real-World Implementation of Particle-Based Microfluidics: On-Spot Test for Iron and Copper Ions in Water.

Author

Saar I and Evard H

Abstract

Water is an essential part of everyday life, and similarly, numerous industries depend on it. Regular water analysis is needed for both home use and in more specific fields, e.g., in agriculture, to ensure necessary quality. For an inexpensive and more convenient alternative to laboratory analysis, reliable and easy-to-use on-spot analysis devices are required. In this study, a novel particle-based microfluidic test for the quantitative analysis of iron and copper ions was developed. This is the first time that particle-based microfluidics has been demonstrated in a self-contained test to analyze real-world samples. The working range for both analytes was from 0.05 to 5 ppm with detection limits of 38 ppb for copper and 10 ppb for iron. This was achieved through a novel approach with sequentially placed immobile colorimetric reagents that can concentrate the analytes from the sample. In addition to the excellent suitability of monitoring drinking water, the applicability of the test to samples containing chelating agents was demonstrated. Different tap water samples and nutrient solutions from a hydroponic farm were used to successfully cross-validate tests' performance with accredited laboratory methods. To the authors' knowledge, such on-spot tests for complex samples containing strong chelating agents have not been successfully demonstrated before. Overall, the tests required under a minute of hands-on time, and no expertise is needed to perform the analysis. An ordinary portable flatbed scanner was used for quantification, allowing the entire analysis to be performed on the spot., Competing Interests: The authors declare the following competing financial interest(s): The authors have applied for a patent covering the main production aspects of the device and are planning to commercialize the technology via a start-up company., (© 2025 The Authors. Published by American Chemical Society.)

Published
2025
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results